West Pharma Reports Operations Rebounding Post-Cyberattack

• The cyberattack forced West to take systems offline and restrict access, temporarily disrupting operations before the unauthorized activity was contained
• Key facilities including the Eschweiler, Germany site are fully operational, with standard packaging and most West Vantage sites resuming shipments
• Evercore ISI analyst expects some impact to Q2 results but no hit to full-year outlook, noting the effect is likely already priced into the stock decline

West Pharmaceutical Services Reports Recovery from Cyberattack

West Pharmaceutical Services announced Friday that operations are steadily recovering following a cyberattack detected on May 4 that temporarily disrupted global manufacturing and logistics. The incident forced the company to take systems offline and restrict access as a precautionary measure.

Operational Status:

The company's high-value product sites, including its largest facility in Eschweiler, Germany, are now fully operational. Standard packaging sites and most West Vantage facilities have resumed shipments. West confirmed the unauthorized activity has been contained and immediate risks mitigated, though no timeline for complete restoration was provided.

Financial Impact:

West Pharmaceutical did not disclose specific financial damages from the incident. Evercore ISI analyst Daniel Markowitz expects some impact on second-quarter results but anticipates no effect on full-year guidance. He noted the impact appears already reflected in the stock's recent decline and suggested flexible capacity could enable operations to catch up within the quarter, presenting potential upside.

Industry Context:

The cyberattack adds West Pharmaceutical to a growing list of medical device and pharmaceutical companies facing cybersecurity threats. Stryker and Intuitive Surgical reported similar incidents in March, while Medtronic disclosed a breach in April, highlighting increasing cybersecurity vulnerabilities across the healthcare supply chain.

Market Implications:

The incident underscores operational risks facing pharmaceutical manufacturers and the growing importance of cybersecurity infrastructure. Investors should monitor second-quarter earnings for any operational disruptions, though analysts suggest limited long-term financial impact given the company's recovery progress and operational flexibility.